Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

Targeted Oncology: For the community oncologist, the choice between niraparib and olaparib often comes down to the patient's molecular profile. In a pMMR/HRD-negative patient, what clinical markers ...

Citius Oncology announced a distribution agreement with Uniphar, a Dublin-based international healthcare services company, to provide access to denileukin diftitox (Lymphir) across Western and Eastern ...

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer. Although ...

The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...

WVU Medicine pioneers nonthermal PEF therapy for metastatic lung nodules, using robotic bronchoscopy to target tumors precisely and potentially boost immune response.

Cancer survival reaches 70% at 5 years, as targeted and immunotherapies boost outcomes and shift care toward survivorship and long-term quality of life.

Saiesh Reddy Voppuru, MD, is a thoracic oncologist at the WVU Heart and Vascular Institute.

Decreases in circulating tumor DNA (ctDNA) within the first month of immune checkpoint inhibitor (ICI) therapy were strongly ...

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...